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Background
The Canadian HIV Vaccine Initiative (CHVI) is a five-year
initiative between the Government of Canada and the Bill
& Melinda Gates Foundation, and it represents a signifi-
cant Canadian contribution to the Global HIV Vaccine
Enterprise that seeks to accelerate the development of safe,
effective, affordable and globally accessible HIV vaccines.
Through its Community and Social Dimensions program
area, the CHVI has implemented strategies to engaging
community-based AIDS organizations (CBAO's) through
dialogue/consultation and a new HIV vaccine Commu-
nity Initiatives Fund.
Methods
Face-to-face and on-line consultations were held with rep-
resentatives of CBAO's to determine the most effective
method of their engagement in the CHVI.
Results
The consultations identified key considerations including:
the importance of supporting innovative strategies of
community engagement for HIV vaccines, the need to
build on existing activities related to new prevention tech-
nologies, the value of domestic-international collabora-
tions and linkages, and the inclusion of a global
dissemination and access component.
Conclusion
The consultations informed the development of a new
funding program launched in winter 2009 to provide
funding support to CBAO's in policy development, legal
ethical and human rights, and community awareness and
preparedness. This milestone signals the commitment of
the CHVI to ensure the engagement of vulnerable com-
munities in HIV vaccines work in Canada. In addition, the
CHVI is considering other strategies to engage communi-
ties such as developing knowledge resources for front-line
AIDS and public health organizations, the support of
community-based networks and the inclusion of HIV vac-
cines new prevention technologies in upcoming Cana-
dian skills building and other HIV/AIDS research
symposium.
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